Início › Câncer de Pulmão › Idaho › Boise
Ensaios clínicos de Câncer de Pulmão em Boise, ID
11 estudos para Câncer de Pulmão estão buscando participantes em locais em Boise e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecrutandoFase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecrutandoFase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecrutandoFase 3
- Saint Luke's Cancer Institute - Boise, Boise
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RecrutandoFase 2/3
- St. Luke's Cancer Institute: Boise, Boise
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecrutandoFase 3
- St. Luke's Cancer Institute, Boise
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecrutandoFase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2/3
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Boise
Ensaios de Câncer de Pulmão em outras cidades
- Houston, TX78 estudos
- Boston, MA62 estudos
- New York City, NY60 estudos
- Los Angeles, CA45 estudos
- Washington, DC41 estudos
- Arlington, VA41 estudos
- Chicago, IL41 estudos
- Nashville, TN40 estudos
- Baltimore, MD40 estudos
- St. Louis, MO39 estudos
- Columbus, OH37 estudos
- Philadelphia, PA36 estudos
Outros estudos em Boise
- Câncer de Pulmão de Não Pequenas Células14 estudos
- Câncer de Próstata8 estudos
- Leucemia Mieloide Aguda8 estudos
- Câncer de Cólon7 estudos
- Câncer de Mama6 estudos
- Melanoma6 estudos
- Câncer Colorretal6 estudos
- Síndrome do desconforto respiratório6 estudos
- Linfoma de Burkitt5 estudos
- Lesão Cerebral Traumática4 estudos
- Síndrome Pós-Concussão4 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço4 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.